{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:56:08Z","timestamp":1794606968847,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ijantimicag.2021.106512","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T09:28:47Z","timestamp":1640683727000},"page":"106512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"Lorenzo","family":"Onorato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Macera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-2537","authenticated-orcid":false,"given":"Paolo","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2021.106512_bib0001","doi-asserted-by":"crossref","first-page":"20316","DOI":"10.2807\/ese.17.46.20316-en","article-title":"The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use","volume":"17","author":"Zarb","year":"2012","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0003","doi-asserted-by":"crossref","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0005","series-title":"Surveillance of antimicrobial resistance in Europe 2018","year":"2019"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0006","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1128\/AAC.00065-10","article-title":"The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression","volume":"54","author":"Louie","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/AAC.05252-11","article-title":"Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa","volume":"56","author":"Drusano","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0008","doi-asserted-by":"crossref","first-page":"e00113","DOI":"10.1128\/AAC.00113-18","article-title":"Antibacterial activity of human simulated epithelial lining fluid concentrations of ceftazidime-avibactam alone or in combination with Amikacin Inhale (BAY41-6551) against carbapenem-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae","volume":"62","author":"Almarzoky Abuhussain","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0009","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10096-017-2907-x","article-title":"Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study","volume":"36","author":"Paulsson","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0010","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1093\/jac\/dkx315","article-title":"Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis","volume":"72","author":"Ripa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0011","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2012.12.006","article-title":"Falagas ME. \u03b2-lactam plus aminoglycoside or fluoroquinolone combination versus \u03b2-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis","volume":"41","author":"Vardakas","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0012","first-page":"2418","article-title":"Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: a cumulative meta-analysis of cohort studies","volume":"15","author":"Tang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0013","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0014","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0015","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0016","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised Cochrane risk-of-bias tool for randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0017","series-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2014"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0018","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2021"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0019","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0020","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/infdis\/130.Supplement.S14","article-title":"Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report","volume":"130","author":"Tapper","year":"1974","journal-title":"J Infect Dis"},{"issue":"Suppl. A","key":"10.1016\/j.ijantimicag.2021.106512_bib0021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/12.suppl_A.101","article-title":"A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients","volume":"12","author":"Fainstein","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0022","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archinte.1985.00360090089015","article-title":"Pseudomonas bacteremia. Retrospective analysis of 410 episodes","volume":"145","author":"Bodey","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0023","first-page":"65","article-title":"Imipenem\/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study","volume":"52","author":"Norrby","year":"1988","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0024","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients from the infectious disease and special pathogens sections","volume":"87","author":"Hilf","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0025","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/AAC.26.6.870","article-title":"Single-drug versus combination empirical therapy for Gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia","volume":"26","author":"Piccart","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0026","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/clinids\/18.6.886","article-title":"Pseudomonas aeruginosa bacteremia in patients with AIDS","volume":"18","author":"Mendelson","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0027","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy versus \u03b2-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0028","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s100960050164","article-title":"Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital","volume":"17","author":"Kuikka","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0029","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1201-9712(98)90055-8","article-title":"Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy","volume":"2","author":"Siegman-Igra","year":"1998","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1201-9712(99)90017-6","article-title":"Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies","volume":"3","author":"Todeschini","year":"1999","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0031","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archinte.160.4.501","article-title":"Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes","volume":"160","author":"Chatzinikolaou","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0032","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/322646","article-title":"A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia","volume":"33","author":"Del Favero","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0033","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.47.9.2756-2764.2003","article-title":"Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia","volume":"47","author":"Chamot","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0034","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2334-6-52","article-title":"Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-I extended-spectrum beta-lactamase","volume":"6","author":"Endimiani","year":"2006","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0036","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","article-title":"Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy","volume":"35","author":"Garnacho-Montero","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0037","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/157488408784293660","article-title":"Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients","volume":"3","author":"Chaudhary","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0038","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/157488409787236119","article-title":"Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections","volume":"4","author":"Chaudhary","year":"2009","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0039","doi-asserted-by":"crossref","first-page":"e26470","DOI":"10.1371\/journal.pone.0026470","article-title":"Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia","volume":"6","author":"Bliziotis","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0040","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1471-2334-12-308","article-title":"Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia","volume":"12","author":"Park","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0041","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1128\/AAC.02235-12","article-title":"Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia","volume":"57","author":"Bowers","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0042","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cid\/cit223","article-title":"Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort","volume":"57","author":"Pe\u00f1a","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0043","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2334-14-161","article-title":"Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0044","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s15010-014-0635-z","article-title":"Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections","volume":"42","author":"Samonis","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.47102\/annals-acadmedsg.V43N11p526","article-title":"Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia","volume":"43","author":"Tan","year":"2014","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0046","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12879-017-2597-0","article-title":"Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0047","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diagmicrobio.2016.10.008","article-title":"Tree-structured survival analysis of patients with Pseudomonas aeruginosa bacteremia: a multicenter observational cohort study","volume":"87","author":"Yoon","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0048","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"D\u00edaz-Ca\u00f1estro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203295","article-title":"Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections","volume":"13","author":"Tschudin-Sutter","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00431-020-03598-4","article-title":"Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study","volume":"179","author":"Pilmis","year":"2020","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0051","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/jac\/dkab134","article-title":"Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study","volume":"76","author":"Babich","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0052","article-title":"Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia","volume":"2013","author":"Paul","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0053","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0054","first-page":"e01268","article-title":"Evaluation of pharmacokinetic\/pharmacodynamic model-based optimized combination regimens against multidrug-resistant Pseudomonas aeruginosa in a murine thigh infection model by using humanized dosing schemes","volume":"61","author":"Yadav","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106512_bib0055","article-title":"Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis","volume":"2014","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921013534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921013534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:26:41Z","timestamp":1741346801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857921013534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0924857921013534"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106512","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106512"}}